DrugPatentWatch Database Preview
SERNIVO Drug Profile
» See Plans and Pricing
When do Sernivo patents expire, and when can generic versions of Sernivo launch?
Sernivo is a drug marketed by Encore Dermat and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.
This drug has seven patent family members in five countries.
The generic ingredient in SERNIVO is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sernivo
A generic version of SERNIVO was approved as betamethasone dipropionate by FOUGERA PHARMS on June 26th, 1984.
Summary for SERNIVO
| International Patents: | 7 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 44 |
| Patent Applications: | 3,945 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SERNIVO |
| Drug Sales Revenues: | Drug sales revenues for SERNIVO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SERNIVO |
| What excipients (inactive ingredients) are in SERNIVO? | SERNIVO excipients list |
| DailyMed Link: | SERNIVO at DailyMed |
Pharmacology for SERNIVO
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Paragraph IV (Patent) Challenges for SERNIVO
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| SERNIVO | SPRAY;TOPICAL | betamethasone dipropionate | 208079 | 2018-02-15 |
US Patents and Regulatory Information for SERNIVO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encore Dermat | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Encore Dermat | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Encore Dermat | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Encore Dermat | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Encore Dermat | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Encore Dermat | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Encore Dermat | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SERNIVO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3141246 | Start Trial |
| Japan | 2013503203 | Start Trial |
| Denmark | 2473161 | Start Trial |
| Japan | 5833007 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2011026076 | Start Trial |
| Spain | 2637447 | Start Trial |
| European Patent Office | 2473161 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
